Legal Psychedelics in the US: State by State Status and Key Laws
A definitive guide to the legal status of psychedelics in the United States, including federal scheduling, state-level reforms, and what researchers, clinicians, and investors need to know.
Are Psychedelics Legal in the United States?
No, psychedelics such as psilocybin and LSD remain illegal under United States federal law. Most classic psychedelics—including psilocybin (the active compound in "magic mushrooms"), LSD (lysergic acid diethylamide), DMT (N,N-dimethyltryptamine), and mescaline—are classified as Schedule I controlled substances under the Controlled Substances Act (CSA) of 1970. This means they are considered to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. No psychedelic has received approval from the Food and Drug Administration (FDA) for general medical use as of this writing. This article is for general informational purposes only and does not constitute legal advice. Always consult a qualified attorney for specific legal guidance.
However, some US states have enacted reforms that create exceptions for certain uses of psychedelics, particularly psilocybin, under strictly regulated frameworks. These state-level programs do not override federal law, but they do shape the practical landscape for research, therapy, and investment.
Federal Law: Schedule I Status and FDA Pathways
Under federal law, psychedelics such as psilocybin, LSD, DMT, and mescaline are listed in Schedule I of the CSA (21 U.S.C. §812). This is the strictest classification, shared with substances like heroin. Schedule I status makes it a federal crime to manufacture, possess, distribute, or use these substances outside of tightly controlled research settings. The Drug Enforcement Administration (DEA) enforces these restrictions, and the FDA has not approved any classic psychedelic for medical use.
There are ongoing clinical trials for psychedelic-assisted therapies. Notably, Compass Pathways is conducting Phase 3 trials of COMP360 (a synthetic psilocybin formulation) for treatment-resistant depression, with readouts expected through 2025-2026. Usona Institute is also running a Phase 3 trial (IPR001) for major depressive disorder. Until these or similar products receive FDA approval and are rescheduled, federal law remains unchanged.
For a broader overview of clinical research and policy trends, see our Psychedelic Research Landscape and Briefing sections.
State-Level Psychedelic Laws: Where Are Exceptions?
While federal law sets the baseline, individual states can pass laws that decriminalize or regulate psychedelics within their borders. These reforms do not make psychedelics "legal" in the federal sense, but they can reduce penalties or create state-sanctioned programs. Here are the most significant state-level developments:
Oregon: Psilocybin Services (Measure 109)
Oregon became the first state to legalize supervised adult use of psilocybin for therapeutic purposes with Measure 109, passed by voters in 2020. The Oregon Psilocybin Services Act established a regulatory framework for licensed facilitators to administer psilocybin in controlled settings. The program launched in 2023. Personal possession of small amounts of psilocybin is also decriminalized, but unlicensed sale or distribution remains illegal. See our Psychedelic Law Guide for details.
Colorado: Natural Medicine Program (Proposition 122)
Colorado voters approved Proposition 122 in 2022, which decriminalized personal use, possession, and sharing (but not commercial sale) of certain natural psychedelics, including psilocybin, DMT, ibogaine, and mescaline (not derived from peyote). The state is developing a regulated system for licensed healing centers, expected to open between 2024 and 2025. Until then, only non-commercial, personal use is protected from criminal penalties.
Other States and Localities
Several cities—including Denver (CO), Oakland and Santa Cruz (CA), Seattle (WA), and others—have decriminalized possession of certain psychedelics, usually by making enforcement the lowest law enforcement priority. These measures do not create legal supply chains or authorize commercial activity. No other state currently has a regulated therapeutic program for psychedelics, though legislative proposals are active in California, Massachusetts, and elsewhere.
Common Questions About Psychedelic Legality
- Is psilocybin therapy legal anywhere in the US? Only in Oregon (licensed facilitators, under state law) and soon in Colorado (licensed healing centers in development). Elsewhere, psilocybin remains illegal federally and in most states.
- Can doctors prescribe psychedelics? No. There is no FDA-approved psychedelic medication available for prescription outside of clinical trials or expanded access programs.
- What about ketamine? Ketamine is a Schedule III drug and is FDA-approved as an anesthetic. Off-label use for depression is legal, but ketamine is not a classic psychedelic. See our Guides for more on ketamine clinics.
- Are there religious exemptions? Certain religious groups, such as the Native American Church (for peyote) and União do Vegetal (for ayahuasca), have won federal court exemptions for sacramental use. These are narrow and do not apply to the general public.
Research, Policy, and What Comes Next
The legal landscape for psychedelics in the US is evolving. Recent FDA hearings and ongoing Phase 3 trials signal growing institutional interest in regulated access to psychedelic therapies. However, the DEA continues to propose new scheduling actions, and federal law remains unchanged for now. This regulatory divergence creates uncertainty for researchers, clinicians, and investors.
For those interested in the future of psychedelic law, research, and investment, we recommend:
- Monitoring clinical trial progress and FDA guidance (Research Landscape)
- Staying updated on state and local legislative changes (Briefing Feed)
- Reviewing our comprehensive Psychedelic Law Guide
- Exploring practical resources in our Tools section
Summary: Psychedelics remain federally illegal in the US, with narrow state-level exceptions for psilocybin in Oregon and Colorado. All other use is generally prohibited, pending the outcome of ongoing clinical trials and potential FDA action.